Mycobacterium interjectum is a rare and newly discovered human infection, first being discovered in 1993. Having only been reported in nine pediatric cases, and en even smaller amount being discovered in adults, treatment on this infection is very limited and unknown. Only 2 cases of M. Interjectum among adults have been reliably described. One of the cases occurred in 2005 in Spain, the patient responded to a 6-month “empiric treatment” consisting of rifampicin, isoniazid, and pyrazinamide. After almost two years, the patient returned with the same illness, and now showing resistance to all of the previously named antibiotics. The patient was then put on a combination of clarithromycin, levofloxacin, and streptomycin. Patients who fail to
